U. Jariwala, J. Prescott, and L. Jia, Identification of novel androgen receptor target genes in prostate cancer, Molecular Cancer, vol.6, issue.1, p.39, 2007.
DOI : 10.1186/1476-4598-6-39

M. Wilson, R. Haller, and S. Li, ELEVATION OF DIPEPTIDYLPEPTIDASE IV ACTIVITIES IN THE PROSTATE PERIPHERAL ZONE AND PROSTATIC SECRETIONS OF MEN WITH PROSTATE CANCER: POSSIBLE PROSTATE CANCER DISEASE MARKER, The Journal of Urology, vol.174, issue.3, pp.1124-1128, 2005.
DOI : 10.1097/01.ju.0000168621.84017.5c

R. Bullard, W. Gibson, and S. Bose, Functional analysis of the host defense peptide Human Beta Defensin-1: New insight into its potential role in cancer, Molecular Immunology, vol.45, issue.3, pp.839-848, 2008.
DOI : 10.1016/j.molimm.2006.11.026

R. Schmidt, Y. Zhang, and Y. Zhao, A Novel Splicing Variant of Proprotein Convertase Subtilisin/Kexin Type 9, DNA and Cell Biology, vol.27, issue.4
DOI : 10.1089/dna.2007.0667

M. Harper, E. Glynne-jones, and L. Goddard, Relationship of proliferating cell nuclear antigen (PCNA) in prostatic carcinomas to various clinical parameters, The Prostate, vol.59, issue.3, pp.243-253, 1992.
DOI : 10.1002/pros.2990200309

S. Phillips, C. Barton, and S. Lee, Loss of the retinoblastoma susceptibility gene (RB1) is a frequent and early event in prostatic tumorigenesis, British Journal of Cancer, vol.70, issue.6, pp.1252-1257, 1994.
DOI : 10.1038/bjc.1994.482

L. Zeng, R. Rowland, and S. Lele, Apoptosis incidence and protein expression of p53, TGF-?? receptor II, p27Kip1, and Smad4 in benign, premalignant, and malignant human prostate1 1Accepted for publication 0, 2003., Human Pathology, vol.35, issue.3, pp.290-297, 2004.
DOI : 10.1016/j.humpath.2003.11.001

D. Mcculloch, P. Akl, and H. Samaratunga, Expression of the Disintegrin Metalloprotease, ADAM-10, in Prostate Cancer and Its Regulation by Dihydrotestosterone, Insulin-Like Growth Factor I, and Epidermal Growth Factor in the Prostate Cancer Cell Model LNCaP, Clinical Cancer Research, vol.10, issue.1, pp.314-323, 2004.
DOI : 10.1158/1078-0432.CCR-0846-3

S. Sakamoto, M. Yokoyama, and K. Prakash, Development of Quantitative Detection Assays for CYR61 as a New Marker for Benign Prostatic Hyperplasia, Journal of Biomolecular Screening, vol.8, issue.6, pp.701-711, 2003.
DOI : 10.1177/1087057103259159

D. Tiniakos, D. Mitropoulos, and A. Kyroudi-voulgari, Expression of c-jun oncogene in hyperplastic and carcinomatous human prostate, Urology, vol.67, issue.1, pp.204-208, 2006.
DOI : 10.1016/j.urology.2005.07.045

S. Shariat, R. Ashfaq, and C. Roehrborn, EXPRESSION OF SURVIVIN AND APOPTOTIC BIOMARKERS IN BENIGN PROSTATIC HYPERPLASIA, The Journal of Urology, vol.174, issue.5, pp.2046-2050, 2005.
DOI : 10.1097/01.ju.0000176459.79180.d1

A. Bozec, A. Ruffion, and M. Decaussin, Activation of Caspases-3, -6, and -9 during Finasteride Treatment of Benign Prostatic Hyperplasia, The Journal of Clinical Endocrinology & Metabolism, vol.90, issue.1, pp.17-25, 2005.
DOI : 10.1210/jc.2004-0712

J. Shaw and E. Diamandis, Distribution of 15 Human Kallikreins in Tissues and Biological Fluids, Clinical Chemistry, vol.53, issue.8, pp.1423-1432, 2007.
DOI : 10.1373/clinchem.2007.088104

N. Soulitzis, I. Karyotis, and D. Delakas, Expression analysis of peptide growth factors VEGF, FGF2, TGFB1, EGF and IGF1 in prostate cancer and benign prostatic hyperplasia, International Journal of Oncology, vol.29, pp.305-314, 2006.
DOI : 10.3892/ijo.29.2.305

C. Roehrborn, 5-alpha-Reductase Inhibitors Prevent the Progression of Benign Prostatic Hyperplasia, Rev Urol, vol.5, pp.12-21, 2003.

N. Kyprianou and C. Benning, Suppression of human prostate cancer cell growth by alpha1-adrenoceptor antagonists doxazosin and terazosin via induction of apoptosis

G. Fromont, L. Chene, and A. Latil, MOLECULAR PROFILING OF BENIGN PROSTATIC HYPERPLASIA USING A LARGE SCALE REAL-TIME REVERSE TRANSCRIPTASE-POLYMERASE CHAIN REACTION APPROACH, The Journal of Urology, vol.172, issue.4
DOI : 10.1097/01.ju.0000137819.92305.46

J. Luo, T. Dunn, and C. Ewing, Gene expression signature of benign prostatic hyperplasia revealed by cDNA microarray analysis, The Prostate, vol.1, issue.3, pp.189-200, 2002.
DOI : 10.1002/pros.10087

G. Kramer and D. Mitteregger, Is Benign Prostatic Hyperplasia (BPH) an Immune Inflammatory Disease?, European Urology, vol.51, issue.5, pp.1202-1216, 2007.
DOI : 10.1016/j.eururo.2006.12.011

K. Prakash, G. Pirozzi, and M. Elashoff, Symptomatic and asymptomatic benign prostatic hyperplasia: Molecular differentiation by using microarrays, Proceedings of the National Academy of Sciences, vol.99, issue.11
DOI : 10.1073/pnas.112191399